MSMarco Serpa

Marco Serpa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marco Serpa has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Periodic intrafraction image-guided focal dose-escalated stereotactic body radiotherapy for prostate carcinoma on a standard linear accelerator

    by Marco Serpa, Rolf Wiehle, Thomas Rothe, Sophie Küchler, Tobias Fechter, Ilias Sachpazidis, Carlotta Rizzo, Sonja Adebahr, Siegmar Kuhn, Paolina Toncheva, et al.

  • Open Access

    Megavoltage intrafraction monitoring and position uncertainty in gimbaled markerless dynamic tumor tracking treatment of lung tumors

    by Marco Serpa, Tobias Brandt, Simon K. B. Spohn, Andreas Rimner, Christoph Bert

    Background: The clinical realization of markerless dynamic tumor tracking (MLDTT) has prompted a new paradigm shift to intrafraction imaging‐based quality assurance (QA). During MLDTT treatment using a gimbaled accelerator, the megavoltage (MV) imager serves as an independent system to leverage real‐time intrafraction monitoring. Soft‐tissue feature tracking has shown promise for tumor localization in confined MV projections, but studies demonstrating its application in clinical MLDTT treatments are scarse. Purpose: To validate MV image‐based dense soft‐tissue feature tracking for intrafraction position monitoring of lung tumors during MLDTT stereotactic body radiotherapy (SBRT), and report on the resolved geometric uncertainty. Methods: Ten non‐small cell lung cancer (NSCLC) patients underwent MLDTT‐SBRT using a commercial gimbal‐based system. During treatment, beam's‐eye‐view (BEV) projection images were captured at ∼3 frames s −1 (fps) using the electronic portal imaging device (EPID). MV sequences were streamed to a research workstation and processed off‐line using a purpose‐built algorithm, the soft‐tissue feature tracker (SoFT). Both the tumor and dynamic field aperture position were automatically extracted in the pan and tilt directions of the gimbaled x‐ray head, corresponding to the in‐plane lateral and longitudinal direction of the imager, and compared to ground truth manual tracking. The success, percentage of fields producing an output, and performance of MV tracking under the presence/absence of anatomy‐related obstruction and multi‐leaf collimator (MLC) occlusion were quantified, including three‐dimensional conformal (3DCRT) and step‐and‐shoot intensity modulated radiotherapy (IMRT) deliveries. In addition, the geometric uncertainty of MLDTT treatment was estimated as the difference between field aperture and target center position in the BEV. The standard deviation of systematic ( Σ ) and random ( σ ) errors were determined. Results: MV tracking was successful for 89.7% of (unmodulated) 3DCRT fields, as well as 82.4% of (modulated) control points (CPs) and subfields (SFs) for IMRT and field‐in‐field 3DCRT deliveries. The MV tracking accuracy was dependent on the traversed anatomy, tumor visibility, and occlusion by the MLC. The mean MV tracking accuracy was 1.2 mm (pan) and 1.4 mm (tilt), and a resultant 2D accuracy of 1.8 mm. The MV tracking performance within 2 mm was observed in 92.1% (pan) and 86.6% (tilt), respectively. The mean aperture‐target positional uncertainty smaller than 3 mm/5 mm was observed in 94.4/97.9% (pan) and 89.6/96.7% (tilt) of the time. The group Σ and σ were 0.5 mm/0.8 mm (pan), and 0.7 mm/1.2 mm (tilt), compared to 0.3 mm/0.5 mm (pan), and 0.6 mm/0.9 mm (tilt) based on the manual ground truth. Conclusion: MV imaging coupled with the soft‐tissue feature tracker algorithm constitutes a valuable non‐invasive method for independent intrafraction surveillance. Tracking multiple features has shown the potential to improve position estimation, notwithstanding obstruction, and occlusion challenges, facilitating the quantification of the geometric uncertainty of MLDTT treatment.


  • Open Access

    Deep inspiration breath-hold radiation therapy in left-sided breast cancer patients: a single-institution retrospective dosimetric analysis of organs at risk doses

    by Jule Wolf, Sabine Stoller, Jördis Lübke, Thomas Rothe, Marco Serpa, Jutta Scholber, Constantinos Zamboglou, Eleni Gkika, Dimos Baltas, Ingolf Juhasz-Böss, et al.

    Background: Radiotherapy can induce cardiac injury in left-sided breast cancer cases. Cardiac-sparing irradiation using the deep inspiration breath-hold (DIBH) technique can achieve substantial dose reduction to vulnerable cardiac substructures compared with free breathing (FB). This study evaluated the dosimetric differences between both techniques at a single institution. Methods: From 2017 to 2019, 130 patients with left-sided breast cancer underwent breast-conserving surgery (BCS; n = 121, 93.1%) or mastectomy (ME; n = 9, 6.9%) along with axillary lymph node staging (n = 105, 80.8%), followed by adjuvant irradiation in DIBH technique; adjuvant systemic therapy was included if applicable. 106 (81.5%) patients received conventional and 24 (18.5%) hypofractionated irradiation. Additionally, 12 patients received regional nodal irradiation. Computed tomography (CT) scans in FB and DIBH position were performed for all patients. Intrafractional 3D position monitoring of the patient surface in deep inspiration and breath gating was performed using Sentinel and Catalyst HD 3D surface scanning systems (C-RAD, Catalyst, C‑RAD AB, Uppsala, Sweden). Individual coaching and determination of breathing amplitude during the radiation planning CT was performed. Three-dimensional treatment planning was performed using standard tangential treatment portals (6 or 18 MV). The delineation of cardiac structures and both lungs was done in both the FB and the DIBH scan. Results: All dosimetric parameters for cardiac structures were significantly reduced (p < 0.01 for all). The mean heart dose (Dmean) in the DIBH group was 1.3 Gy (range 0.5–3.6) vs. 2.2 Gy (range 0.9–8.8) in the FB group (p < 0.001). The Dmean for the left ventricle (LV) in DIBH was 1.5 Gy (range 0.6–4.5), as compared to 2.8 Gy (1.1–9.5) with FB (p < 0.001). The parameters for LV (V10 Gy, V15 Gy, V20 Gy, V23 Gy, V25 Gy, V30 Gy) were reduced by about 100% (p < 0.001). The LAD Dmean in the DIBH group was 4.1 Gy (range 1.2–33.3) and 14.3 Gy (range 2.4–37.5) in the FB group (p < 0.001). The median values for LAD such as V15 Gy, V20 Gy, V25 Gy, V30 Gy, and V40 Gy decreased by roughly 100% (p < 0.001). An increasing volume of left lung in the DIBH position resulted in dose sparing of cardiac structures. Conclusion: For all ascertained dosimetric parameters, a significant dose reduction could be achieved in DIBH technique.


  • Open Access

    Incidental irradiation of the regional lymph nodes during deep inspiration breath-hold radiation therapy in left-sided breast cancer patients: a dosimetric analysis

    by Jule Wolf, Steffen Kurz, Thomas Rothe, Marco Serpa, Jutta Scholber, Thalia Erbes, Eleni Gkika, Dimos Baltas, Vivek Verma, David Krug, et al.

    Background: Radiotherapy using the deep inspiration breath-hold (DIBH) technique compared with free breathing (FB) can achieve substantial reduction of heart and lung doses in left-sided breast cancer cases. The anatomical organ movement in deep inspiration also cause unintended exposure of locoregional lymph nodes to the irradiation field. Methods: From 2017–2020, 148 patients with left-sided breast cancer underwent breast conserving surgery (BCS) or mastectomy (ME) with axillary lymph node staging, followed by adjuvant irradiation in DIBH technique. Neoadjuvant or adjuvant systemic therapy was administered depending on hormone receptor and HER2-status. CT scans in FB and DIBH position with individual coaching and determination of the breathing amplitude during the radiation planning CT were performed for all patients. Intrafractional 3D position monitoring of the patient surface in deep inspiration and gating was performed using Sentinel and Catalyst HD 3D surface scanning systems (C-RAD, Catalyst, C-RAD AB, Uppsala, Sweden). Three-dimensional treatment planning was performed using standard tangential treatment portals (6 or 18 MV). The delineation of ipsilateral locoregional lymph nodes was done on the FB and the DIBH CT-scan according to the RTOG recommendations. Results: The mean doses (Dmean) in axillary lymph node (AL) level I, II and III in DIBH were 32.28 Gy (range 2.87–51.7), 20.1 Gy (range 0.44–53.84) and 3.84 Gy (range 0.25–39.23) vs. 34.93 Gy (range 10.52–50.40), 16.40 Gy (range 0.38–52.40) and 3.06 Gy (range 0.21–40.48) in FB (p < 0.0001). Accordingly, in DIBH the Dmean for AL level I were reduced by 7.59%, whereas for AL level II and III increased by 22.56% and 25.49%, respectively. The Dmean for the supraclavicular lymph nodes (SC) in DIBH was 0.82 Gy (range 0.23–4.11), as compared to 0.84 Gy (range 0.22–10.80) with FB (p = 0.002). This results in a mean dose reduction of 2.38% in DIBH. The Dmean for internal mammary lymph nodes (IM) was 12.77 Gy (range 1.45–39.09) in DIBH vs. 11.17 Gy (range 1.34–44.24) in FB (p = 0.005). This yields a mean dose increase of 14.32% in DIBH. Conclusions: The DIBH technique may result in changes in the incidental dose exposure of regional lymph node areas.